31635-59-3Relevant academic research and scientific papers
Heterocyclic compounds as inhibitors of factor VIIa
-
Page/Page column 34, (2008/06/13)
The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
Remarkable Selectivity in the Reaction of 1-Trityl-2-lithioimidazoles with t-Butyl Halogenoacetates
Coutts, Ian G. C.,Jieng, Shende,Khandelwahl, Ghanshyam D.,Wood, Michael L.
, p. 857 - 860 (2007/10/02)
2-Lithio-1-triphenylmethylimidazoles react with t-butyl halogenoacetates to give a variety of products, the nature of which is cleanly determined by the halogen atom.With chloroacetate the products are chloromethyl ketones, while bromacetate gives di-t-butyl imidazolesuccinates, and iodoacetate yields iodoimidazoles.In each case 50percent of the parent triphenylmethylimidazole is recovered from the reaction.When the triphenylmethyl substituent is replaced by the N,N-dimethylsulfamoyl group, reaction with bromoacetate is suppressed, but t-butyl chloroacetate and iodoacetate again give chloroketones and aryl iodides respectively.
